Zobrazeno 1 - 10
of 13
pro vyhledávání: ''
Autor:
Gilberto Lopes
Publikováno v:
BMC Cancer
BMC Cancer, Vol 11, Iss 1, p 178 (2011)
BMC Cancer, Vol 11, Iss 1, p 178 (2011)
Background Trastuzumab has revolutionized the way we treat early Her2Neu-positive breast cancer, as it significantly improves disease-free and overall survival. Little is known about the societal costs and benefits of treatment with trastuzumab in th
Autor:
Yalai Bai, William M. Sikov, David L. Rimm, Maysa M. Abu-Khalaf, Lyndsay Harris, Veerle Bossuyt, Huan Cheng, Natalie Sinclair
Publikováno v:
BMC Cancer
Background Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive (HER2+) breast cancers but traditional methods of measuring HER2 expression
Autor:
Yoko Nakasu, Koichi Mitsuya, Nakamasa Hayashi, Junichiro Watanabe, Hideyuki Harada, Ichiro Ito
Publikováno v:
BMC Cancer
Background Multiple new targeted agents have been developed for patients with human epidermal growth factor receptor type 2 (HER2) – positive breast cancer. Patients with HER2– positive breast cancer will develop brain metastases with greater inc
Autor:
Jin Seok Ahn, Yoon-La Choi, Hyun Jung Jun, Yeon Hee Park, Myung Hee Chang, Eun Yoon Cho, Min Jae Park, Young-Hyuck Im, Ji Eun Uhm, Do Hyoung Lim, Sang Hoon Ji, Kyoung Ha Kim, Seong Yoon Yi
Publikováno v:
BMC Cancer
BMC Cancer, Vol 10, Iss 1, p 527 (2010)
BMC Cancer, Vol 10, Iss 1, p 527 (2010)
Background We analyzed the responses to first line treatment and clinical outcomes of metastatic breast cancer patients treated with palliative doxorubicin/cyclophosphamide (AC) according to molecular cancer subtype. Methods A retrospective analysis
Autor:
Adrienne Morey, Diana J. Hastrich, David Ingram, Peter C. Willsher, Arlene Chan, Belinda Brown
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 555 (2012)
BMC Cancer
BMC Cancer
Background Overall survival of HER2 positive metastatic breast cancer patients has been significantly improved with inclusion of trastuzumab to chemotherapy. Several studies have demonstrated discordant HER2 status in the primary and metastatic tumou
Publikováno v:
BMC Cancer
Background A high neutrophil-to-lymphocyte ratio (NLR) may be related to increased mortality in patients with lung, colorectal, stomach, liver, and pancreatic cancer. To date, the utility of NLR to predict the response to neoadjuvant chemotherapy (NA
Autor:
Fountzilas, George, Dafni, U., Bobos, M., Kotoula, V., Batistatou, Anna, Xanthakis, I., Papadimitriou, C., Kostopoulos, I., Koletsa, T., Tsolaki, E., Televantou, D., Timotheadou, E., Koutras, A. K., Klouvas, G. D., Samantas, E., Pisanidis, N., Karanikiotis, C., Sfakianaki, I., Pavlidis, Nicholas, Gogas, H., Linardou, H., Kalogeras, K. T., Pectasides, Dimitrios, Dimopoulos, M. A.
Publikováno v:
BMC Cancer
Background: The HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other agents, such as paclitaxel and anthracyclines. The TOP2A gene has been associated with respons
A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer
Autor:
Luigi Frati, Silverio Tomao, Edmondo Terzoli, Giuliana Caprio, Marisa Di Seri, Federica Tomao, Adriana Romiti, Gian Paolo Spinelli
Publikováno v:
BMC Cancer, Vol 6, Iss 1, p 137 (2006)
BMC Cancer
BMC Cancer
Background Many emerging new drugs have recently been trialled for treatment of early and advanced breast cancer. Among these new agents paclitaxel and gemcitabine play a crucial role, mostly in patients with relapsed and metastatic disease after fai
Autor:
Curt Balch, Sang-Jin Lee, Young Zoo Ahn, Hee Seo Park, Sungjin Park, Hae Ryung Chang, Ja-Lok Ku, Hae Rim Jung, Seungyoon Nam, Garth Powis, Yon Hui Kim
Publikováno v:
BMC Cancer
BMC CANCER(16)
BMC CANCER(16)
Background “Biomarker-driven targeted therapy,” the practice of tailoring patients’ treatment to the expression/activity levels of disease-specific genes/proteins, remains challenging. For example, while the anti-ERBB2 monoclonal antibody, tras
Autor:
Christopher Lanigan, Raymond R. Tubbs, Zhen Wang, Eugen C. Minca, G. Thomas Budd, Larry E. Morrison, Benjamin C. Calhoun, Bryce P. Portier
Publikováno v:
BMC Cancer
Background Pathologic complete response (pCR) after neoadjuvant chemotherapy for breast cancer is associated with improved prognosis in aggressive tumor subtypes, including ERBB2- positive tumors. Recent adoption of pCR as a surrogate endpoint for cl